An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19
| Autor: | Fu, Weihui 1, Liu, Yan 1, Liu, Li 1, Hu, Huiliang 1, Cheng, Xiaobo 1, Liu, Ping 1, Song, Zhigang, Zha, Lijun, Bai, Shimeng, Xu, Tingting, Yuan, Songhua, Lu, Fengru, Shang, Zhiying, Zhao, Yihong, Wang, Jing, Zhao, Jun, Ding, Longfei, Chen, Jun, Zhang, Lin, Zhu, Tongyu ⁎, Zhang, Xiaoyan ⁎, Lu, Hongzhou ⁎, Xu, Jianqing ⁎ |
|---|---|
| Zdroj: | In EClinicalMedicine October 2020 27 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|